IDO inhibitors (e.g., epacadostat) reduce tumor growth and promote the proliferation of CD8+ T cells and NK cells in human peripheral blood mononuclear cells (PBMCs) ex vivo and are currently under clinical trial (Table 2) [148]. The gene discussed is IDO1; the disease is neoplasm.